ARCT - Arcturus Therapeutics Ltd.
| Previous Close | 4.90 |
| Open | 4.97 |
| Bid | 4.71 x 1000 |
| Ask | 7.19 x 900 |
| Day's Range | 4.82 - 5.25 |
| 52 Week Range | 4.11 - 10.00 |
| Volume | 154,623 |
| Avg. Volume | 24,498 |
| Market Cap | 54.976M |
| Beta (3Y Monthly) | 2.47 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.87 |
| Earnings Date | Dec 24, 2018 - Dec 26, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 21.50 |
- GlobeNewswire•5 days ago
Arcturus Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO, Feb. 11, 2019 -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards.
- GlobeNewswire•5 days ago
Arcturus Therapeutics Reassumes Full Worldwide Rights to ARCT-810, a Clinical Development Candidate for Ornithine Transcarbamylase (OTC) Deficiency
Arcturus Therapeutics Ltd. (ARCT), a leading RNA medicines company focused on the discovery, development and commercialization of therapeutics towards rare diseases, today announced that it will reassume 100% global rights for its flagship asset, clinical development candidate ARCT-810, a messenger RNA (mRNA) drug to treat OTC Deficiency. ARCT-810 was previously subject to a 50/50 collaboration between Arcturus and CureVac AG.
- GlobeNewswire•last month
Arcturus Therapeutics Appoints Andrew Sassine as Chief Financial Officer
SAN DIEGO, Jan. 03, 2019 -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards.
- GlobeNewswire•last month
Arcturus Therapeutics to Develop ARCT-810 for Treatment of Ornithine Transcarbamylase (OTC) Deficiency
Arcturus Therapeutics Ltd. (ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare, liver and respiratory diseases with significant unmet medical need, today announced the nomination of its first development candidate, ARCT-810, to treat ornithine transcarbamylase deficiency (OTCD). OTCD is the most common urea cycle disorder. Urea cycle disorders are a group of inherited metabolic disorders that make it difficult for afflicted patients to remove toxic waste products, as proteins are digested. ARCT-810 is based on Arcturus’s propriety lipid library which utilizes the company's LUNAR® delivery platform to safely and effectively deliver OTC messenger RNA to liver cells.
- Simply Wall St.•2 months ago
Do Insiders Own Lots Of Shares In Arcturus Therapeutics Ltd. (NASDAQ:ARCT)?
Every investor in Arcturus Therapeutics Ltd. (NASDAQ:ARCT) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it's not unusual to see Read More...
- GlobeNewswire•2 months ago
Arcturus Therapeutics to Host a Key Opinion Leader Call on Ornithine Transcarbamylase (OTC) Deficiency on December 11
SAN DIEGO, Dec. 03, 2018 -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards.
- Simply Wall St.•4 months ago
Is Arcturus Therapeutics Ltd (NASDAQ:ARCT) A Financially Sound Company?
The direct benefit for Arcturus Therapeutics Ltd (NASDAQ:ARCT), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-off Read More...
